



*ifw*

PATENT  
Attorney Docket No.: UBC1180-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hancock et al.	Art Unit:	1614
Application No.:	10/661,471	Examiner:	Not Yet Assigned
Filed:	September 12, 2003	Conf. No.:	7167
Title:	EFFECTORS OF INNATE IMMUNITY DETERMINATION		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL SHEET**

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) Information Disclosure Statement (2 pgs.);
- (2) PTO Form 1449 (2 pgs.);
- (3) Eight (8) References;
- (4) International Search Report (9 pgs.); and
- (5) Return postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on **March 16, 2005**, in an envelope addressed to: Mail Stop: Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

  
Lisa E. Jambeau


In re Application of:  
Hancock et al.  
Application No.: 10/661,471  
Filed: September 12, 2003  
Page 2

PATENT  
Attorney Docket No.: UBC1180-2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated December 16, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 07-1896.

Respectfully submitted,

Date: March 16, 2005



Lisa A. Haile, J.D. Ph.D.  
Registration No. 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

DLA PIPER RUDNICK GRAY CARY US LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
**USPTO Customer No. 28213**



PATENT  
Attorney Docket No.: UBC1180-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hancock et al.	Art Unit:	1614
Application No.:	10/661,471	Examiner:	Not Yet Assigned
Filed:	September 12, 2003	Conf. No.:	7167
Title:	EFFECTORS OF INNATE IMMUNITY DETERMINATION		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**


Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on **March 16, 2005**, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


  
Lisa E. Jambeau

In re Application of:  
Hancock et al.  
Application No.: 10/661,471  
Filed: September 12, 2003  
Page 2

PATENT  
Attorney Docket No.: UBC1180-2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated December 16, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 07-1896.

Respectfully submitted,



Date: March 16, 2005

Lisa A. Haile, J.D., Ph.D.  
Registration No.: 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

BEST AVAILABLE COPY

DLA PIPER RUDNICK GRAY CARY US LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO Customer Number 28213

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>UBC1180-2</b>	Serial No.: <b>10/661,471</b>
	Applicant: <b>Hancock et al.</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: <b>September 12, 2003</b>	Group Art Unit: <b>1614</b>



### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
	AA	CA2456477A1	02/27/03	Canada			No
	AB	CA2468907A1	06/12/03	Canada			No

BEST AVAILABLE COPY

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AC	Scott MG. et al., "The Human Antimicrobial Peptide LL-37 Is a Multifunctional Modulator of Innate Immune Responses", <i>The Journal of Immunology</i> , Vol. 169, 3883-3891, 2002
	AD	Hancock R.E. et al., "The role of cationic antimicrobial peptides in innate host defenses", <i>Trends in Microbiology</i> , Vol. 8, No. 9, 402-410, September 2000
	AE	Hancock, R.E., "Host Defense (Cationic) Peptides, What is Their Future Clinical Potential?", <i>Drugs</i> , Vol. 57, No. 4, 469-473, April 1999
	AF	Finlay, B.B. et al., "Perspectives, Can innate immunity be enhanced to treat microbial infections?", <i>Nature Reviews Microbiology</i> , Vol. 2, 497-504, June 2004
	AG	Giacometti et al., "Potential Therapeutic Role of Cationic Peptides in Three Experimental Models of Septic Shock", <i>Antimicrobial Agent and Chemotherapy</i> , 2132-2136, July 2002

EXAMINER  GT\6438738.1 104776-27	DATE CONSIDERED
-------------------------------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Department of Commerce Patent and  
Trademark Office

Docket No.

UBC1180-2

Serial No.:

10/661,471

Applicant: Hancock et al.

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Filing Date:

September 12, 2003

Group Art Unit:

1614

AH

Bowdish, D.M.E., et al., "The Human Cationic Peptide LL-37 Induces Activation of the Extracellular Signal-Regulated Kinases and p38 Kinase Pathways in Primary Human Monocytes", *The Journal of Immunology*, Vol. 172, 3758-3765, 2004

BEST AVAILABLE COPY

EXAMINER

GT6438738.1  
104776-27

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.